Brief: Histopathology And Tumor Biomarker Analysis Confirm Cel-Sci's Multikine Significantly Prolonged Overall Survival In Head & Neck Cancer—Phase 3 Data Presented At ESTRO 2023

CEL-SCI

15/05/2023 14:17

May 15 (Reuters) - CEL-SCI Corp  CVM.A :
    * HISTOPATHOLOGY AND TUMOR BIOMARKER ANALYSIS CONFIRM
CEL-SCI’S
MULTIKINE SIGNIFICANTLY PROLONGED OVERALL SURVIVAL IN HEAD &
NECK CANCER—PHASE 3 DATA PRESENTED AT ESTRO 2023

Source text for Eikon:  ID:nBw8G4WPza 
Further company coverage:  CVM.A 

 ((Reuters.Brief@thomsonreuters.com;))